BIRMINGHAM, Ala.--(Scientific Sessions 2012 in Los Angeles will highlight the critical role the Atherotech patented VAP® Lipid Panel plays in improving cardiovascular risk stratification in heart disease research and clinical practice.)--Research findings presented at the American Heart Association (AHA)
“HDL Cholesterol Subclasses and Mortality after Acute Myocardial Infarction: The TRIUMPH Prospective Multi-Center Registry”
The VAP (Vertical Auto Profile) Lipid Panel is utilized in three independent investigator-initiated scientific presentations at AHA 2012: two oral presentations and one poster presentation. Highly respected researchers Parag Joshi, M.D., Seth Martin, M.D., and Peter Toth, M.D., are presenting the findings during the conference.
Dr. Joshi, Clinical Cardiology Fellow, Johns Hopkins Hospital, will present, “HDL Subclasses are Not All Created Equal: Association of HDL Subclasses and Incident Cardiovascular Events in African Americans from the Jackson Heart Study.” Dr. Joshi will address conference attendees during the abstract oral session Monday, November 5, 2012, from 4:15 to 4:30 p.m. in Room 505.
The oral presentation “HDL Cholesterol Subclasses and Mortality after Acute Myocardial Infarction: The TRIUMPH Prospective Multi-Center Registry” is being discussed by Dr. Martin, Fellow, Division of Cardiology, Johns Hopkins Hospital, on Wednesday, November 7, 2012, from 9:00 to 9:15 a.m. in Room 503.
Director of Preventative Cardiology at CGH Medical Center in Sterling, Illinois, and Atherotech Medical Advisory Board Member Peter Toth, M.D., will present Poster Board 2044 on the “Impact of LDL Pattern on Risk for CHD in the Framingham Offspring Population,” Wednesday, November 7, 2012, from 9:30 a.m. to 11:00 a.m. in Kentia Hall, Core 2. Toth has authored or coauthored more than 200 publications and is also president of the National Lipid Association.
Atherotech will provide conference participants with their own VAP Lipid Panel to experience how important it is to accurately identify cardiovascular disease risk, personalize treatment and improve heart health outcomes. Atherotech representatives will be available to discuss the VAP Lipid Panel in booth #757, and blood draws will be provided to qualified attendees during regular exhibit hours. Because LDL is directly measured, fasting is not required. For information on the VAP Lipid Panel, visit www.Atherotech.com or call 877.901.8510. Atherotech Diagnostics Lab is on Twitter at www.Twitter.com/Atherotech and also on Facebook at www.Facebook.com/Atherotech.
To arrange interviews with any of these presenters or other Atherotech medical experts who will be in attendance and can provide outside comment on these and other sessions, please call 720-231-9990 or e-mail email@example.com. All research results are embargoed until the time they are presented during the conference. All times listed are Pacific Standard Time. Please refer to the American Heart Association for embargo policies pertaining to presentations at the Scientific Sessions.
About Atherotech Diagnostics Lab & the VAP Lipid Panel
Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary and comprehensive VAP® Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP Lipid Panel utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company’s dedication to affordable, comprehensive disease management solutions includes Our Healthy Heart, a patient consultation program and expert lipid management education service to health care providers. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.